Lanreotide: 7 agencies, 2003–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused lanreotide: all 12 decisive outcomes across 5 agencies were positive or positive with restrictions.
PBAC (Australia) has been easier on lanreotide than on its own caseload: it refused 0 of 6 decisive submissions here (0%), against a base rate of 24% across everything it has assessed.
The file has been open for more than a decade: 23 years separate the first record, 2 Jul 2003 at HAS (France), from the most recent, 2026 at PBAC (Australia).
PHARMAC (New Zealand) changed its position: recommended on 1 Nov 2004, restricted by 21 Feb 2019.
No assessment is on file from TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for lanreotide, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 20 records date from 2023 or later.
The programme is broad: 10 distinct indication wordings are recorded for lanreotide by the agencies that label one in English (AWMSG, PBAC and SMC).
10 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess lanreotide, on 2 Jul 2003; CIPM (Spain) did not open a file until 24 Jul 2023 — an unusually long tail of 20 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 13 years in total.
3 of the 7 agencies here assessed lanreotide more than once, PBAC (Australia) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for lanreotide.
The full ledger for lanreotide reads 11 recommended, 5 other, 1 withdrawn and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Acromegaly Functional Carcinoid Tumour Non-functional gastroenteropancreatic neuroendocrine tumour (GEPNET) | Recommended | source |
| CIPM (Spain) | 24 Jul 2023 | Indicación terapéutica autorizada: - Tratamiento de pacientes con acromegalia en los que el tratamiento convencional es … | excluded from SNS provision · art. 92 e | source |
| NYE METODER (Norway) | 19 Jun 2022 | Behandling av akromegali (se full indikasjonstekst under) | introduced | source |
| PHARMAC (New Zealand) | 21 Feb 2019 | Gastroenteropancreatic neuroendocrine tumours, non-functional | PTAC advice: Low | source |
| AWMSG (Wales) | 20 Sep 2018 | Treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-N… | recommended (limited) | source |
15 further decisions for lanreotide, across 4 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- octreotide — same ATC class H01C — Pituitary and hypothalamic hormones
- pasireotide — same ATC class H01C — Pituitary and hypothalamic hormones
- vutrisiran — also decided by CIPM in 2023Q3
- deflazacort — also decided by CIPM in 2023Q3
- ciltacabtagene autoleucel — also decided by CIPM in 2023Q3
- inclisiran — also decided by CIPM in 2023Q3
Coverage: 20 decisions for lanreotide from 7 agencies, 2003 to 2026. Data to 7 Sep 2026. ATC class H01C — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.